{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:17:40Z","timestamp":1785489460571,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Although intravesical injection of onabotulinumtoxinA (BoNT-A) has been proved promising in treating patients with interstitial cystitis\/bladder pain syndrome (IC\/BPS), what kind of patients that may benefit from this treatment remains unclear.  This study investigated the predictors for a successful treatment outcome. Patients with IC\/BPS who failed conventional treatments were enrolled to receive intravesical injection of 100 U of BoNT-A immediately followed by hydrodistention. Variables such as O\u2019Leary-Sant symptom and problem indexes (ICSI and ICPI), pain visual analogue scale (VAS), functional bladder capacity (FBC), voiding diary, and urodynamic parameters were measured at baseline and six months after treatment. A global response assessment (GRA) \u2265 2 at six months was defined as successful. There were101 patients enrolled. Significant improvements were observed in mean ICSI, ICPI, OSS (ICSI + ICPI), pain VAS, FBC, frequency, nocturia and GRA at six months after BoNT-A injections (all p &lt; 0.05).  The successful rate at six months was 46\/101 (45.54%). Multivariate logistic regression revealed the baseline ICSI (odds ratio = 0.770, 95% confidence interval = 0.601\u20130.989) was the only predictor for a treatment outcome. ICSI \u2265 12 was the most predictive cutoff value for a treatment failure, with a ROC area of 0.70 (sensitivity = 69.1%,  specificity = 60.9%).<\/jats:p>","DOI":"10.3390\/toxins7082860","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T11:21:59Z","timestamp":1438255319000},"page":"2860-2871","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["O\u2019Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis\/Bladder Pain Syndrome"],"prefix":"10.3390","volume":"7","author":[{"given":"Yuh-Chen","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Urology, Yangming Branch of Taipei City Hospital, 105 Yu-Sheng Street,  Taipei 11148, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 707,  Section 3, Chung Yang Road, Hualien 97002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(01)01112-8","article-title":"Clinical highlights of the national institute of diabetes and digestive and kidney diseases\/interstitial cystitis association scientific conference on interstitial cystitis","volume":"57","author":"Hanno","year":"2001","journal-title":"Urology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.ju.0000154631.92150.ef","article-title":"Intravesical resiniferatoxin for the treatment of interstitial cystitis: A randomized, double-blind, placebo controlled trial","volume":"173","author":"Payne","year":"2005","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.urology.2004.10.071","article-title":"Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis","volume":"65","author":"Nickel","year":"2005","journal-title":"Urology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","article-title":"A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis","volume":"170","author":"Sant","year":"2003","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0022-5347(17)41029-9","article-title":"Use of amitriptyline in the treatment of interstitial cystitis","volume":"141","author":"Hanno","year":"1989","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1097\/01.ju.0000125139.91203.7a","article-title":"Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A","volume":"171","author":"Sairanen","year":"2004","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","article-title":"Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder","volume":"175","author":"Rapp","year":"2006","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","article-title":"Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats","volume":"172","author":"Chuang","year":"2004","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin a has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000087173","article-title":"Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis","volume":"75","author":"Kuo","year":"2005","journal-title":"Urol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2005.12.002","article-title":"Botulinum a toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study","volume":"49","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.juro.2007.10.032","article-title":"Botulinum a toxin intravesical injection in patients with painful bladder syndrome: 1-year followup","volume":"179","author":"Giannantoni","year":"2008","journal-title":"J. Urol."},{"key":"ref_13","first-page":"197","article-title":"Intravesical onabotulinumtoxin A injections for refractory painful bladder syndrome","volume":"15","author":"Chung","year":"2012","journal-title":"Pain Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/nau.22475","article-title":"Challenges and current evidence on the management of bladder pain syndrome","volume":"33","author":"Chrysanthopoulou","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin a in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34846","DOI":"10.1074\/jbc.M202902200","article-title":"Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a clostridium botulinum toxin a endopeptidase fragment and erythrina cristagalli lectin","volume":"277","author":"Duggan","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential","volume":"120","author":"Meng","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","article-title":"Botulinum toxin type a inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation","volume":"101","author":"Lucioni","year":"2008","journal-title":"BJU Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.urology.2007.04.038","article-title":"Intravesical botulinum toxin a injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis","volume":"70","author":"Liu","year":"2007","journal-title":"Urology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1464-410X.2009.08675.x","article-title":"Urinary nerve growth factor level is increased in patients with interstitial cystitis\/bladder pain syndrome and decreased in responders to treatment","volume":"104","author":"Liu","year":"2009","journal-title":"BJU Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type a injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/ijcp.12113","article-title":"Repeated intravesical onabotulinumtoxin A injections are effective in treatment of refractory interstitial cystitis\/bladder pain syndrome","volume":"67","author":"Kuo","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.36076\/ppj.2013\/16\/E15","article-title":"Repeated onabotulinumtoxin A injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo","year":"2013","journal-title":"Pain Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1016\/S1569-9056(15)61080-6","article-title":"Positive response to first onabotulinumtoxin A treatment persists long-term with repeattreatments in patients with neurogenic detrusor overactivity","volume":"14","author":"Denys","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Peyronnet, B., Roumigui\u00e9, M., Castel-Lacanal, E., Guillotreau, J., Malavaud, B., Marque, P., Rischmann, P., and Gam\u00e9, X. (2014). Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. Neurourol. Urodyn.","DOI":"10.1002\/nau.22712"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1096\/fj.09-134346","article-title":"Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors","volume":"23","year":"2009","journal-title":"FASEB J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","article-title":"Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity","volume":"279","year":"2004","journal-title":"J Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuint.2005.04.021","article-title":"Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A","volume":"47","author":"Smith","year":"2005","journal-title":"Neurochem. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.ju.0000143189.19835.f3","article-title":"Inhibitory effect on intravesically applied botulinum toxin A in chronic bladder inflammation","volume":"173","author":"Vemulakonda","year":"2005","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.toxicon.2013.05.011","article-title":"A closer look to botulinum neurotoxin type A-induced analgesia","volume":"71","author":"Guo","year":"2013","journal-title":"Toxicon"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kuo, H.C., Jiang, Y.H., Tsai, Y.C., and Kuo, Y.C. (2015). Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn.","DOI":"10.1016\/j.urols.2015.06.277"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1442-2042.2009.02326.x","article-title":"Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome","volume":"16","author":"Homma","year":"2009","journal-title":"Int. J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(01)01126-8","article-title":"Psychometric validation of the O\u2019Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium","volume":"57","author":"Lubeck","year":"2001","journal-title":"Urology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2005.07.014","article-title":"Responsiveness of symptom scales for interstitial cystitis","volume":"67","author":"Propert","year":"2006","journal-title":"Urology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol. Urodyn."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/7\/8\/2860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:58Z","timestamp":1760215798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/7\/8\/2860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["toxins7082860"],"URL":"https:\/\/doi.org\/10.3390\/toxins7082860","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}